Global Sunitinib Malate
Global Sunitinib Malate

Sunitinib Malate Comprehensive Study by Application (Kidney Cancer, Pancreas Cancer, Intestinal Cancer), Distribution Channel (Hospital Pharmacy, Retail Drug Stores), Dosage (12.5mg, 25mg, 37.5mg, 50mg), Side Effects (Allergic Reaction, Severe Dizziness, Trouble Breathing, Swelling (Face/Tongue/Throat), Others) Players and Region - Global Market Outlook to 2026

Sunitinib Malate Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 213 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Sunitinib Malate Market Scope?
Sunitinib is a small molecule, oral, multi-targeting receptor tyrosine kinase (RTK) inhibitor that was hereby approved by the FDA on January 26, 2006, for the purpose of treatment of renal cell carcinoma (RCC) as well as imatinib-resistant gastrointestinal stromal tumors (GIST) that sunitinib was first cancer drug that was approved for two different indications at the same time. Sunitinib is approved for the treatment of metastatic RCC. Sutent (sunitinib) is an expensive drug that targets proteins in cancer cells and prevents the cancer cells from growing. It is used to treat specific tumors of the digestive tract called GIST, advanced kidney cancer, and certain neuroendocrine tumors of the pancreas. It is less popular than similar drugs. There is currently no generic alternative to Sutent. Sunitinib malate is also offered as part of the Tocriscreen 2.0 Max, Tocriscreen Kinase Inhibitor Library, and Tocriscreen FDA-approved medicines.

The Sunitinib Malate market study is being classified, by Application (Kidney Cancer, Pancreas Cancer and Intestinal Cancer) and major geographies with country level break-up.

The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies.

Pfizer (United States), PV Pharma (India) and Taj Pharma Group (India) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Sunitinib Malate market by Type, Application and Region.

On the basis of geography, the market of Sunitinib Malate has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).


Based on these studies, Sunitinib received regulatory approval from the US Food and Drug Administration (US FDA) in 2007 and full marketing authorization from the European Medicines Agency (EMA). It continues to be recommended as the first-line treatment option for advanced or metastatic predominantly clear cell RCC in patients with good, moderate, and low-risk disease.

Influencing Market Trend
  • Increasing Prevalence of Kidney Cancer
  • Changes in the Medical Practices

Market Drivers
  • The increasing adoption of advanced therapy techniques
  • Increase in the Consumption of Alcohol and Tobacco
  • Changes in Lifestyle
  • High Adoption of Premium-Priced Drugs
  • Growing Geriatric Population

Opportunities
  • Enhancement in Healthcare Expenditure in Developed Regions
  • Increased R&D Expenditure of Pharmaceutical Companies

Restraints
  • Patent Expiry of Various Major Drugs
  • High Cost of Sunitinib Drugs

Challenges
  • Lack of Awareness among People in Developing Countries


Key Target Audience
Manufacturers of Sunitinib Malate, Suppliers and Distributors of Sunitinib Malate, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.
Report Objectives / Segmentation Covered
By Application
  • Kidney Cancer
  • Pancreas Cancer
  • Intestinal Cancer
By Distribution Channel
  • Hospital Pharmacy
  • Retail Drug Stores

By Dosage
  • 12.5mg
  • 25mg
  • 37.5mg
  • 50mg

By Side Effects
  • Allergic Reaction
  • Severe Dizziness
  • Trouble Breathing
  • Swelling (Face/Tongue/Throat)
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The increasing adoption of advanced therapy techniques
      • 3.2.2. Increase in the Consumption of Alcohol and Tobacco
      • 3.2.3. Changes in Lifestyle
      • 3.2.4. High Adoption of Premium-Priced Drugs
      • 3.2.5. Growing Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness among People in Developing Countries
    • 3.4. Market Trends
      • 3.4.1. Increasing Prevalence of Kidney Cancer
      • 3.4.2. Changes in the Medical Practices
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Sunitinib Malate, by Application, Distribution Channel, Dosage, Side Effects and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Sunitinib Malate (Value)
      • 5.2.1. Global Sunitinib Malate by: Application (Value)
        • 5.2.1.1. Kidney Cancer
        • 5.2.1.2. Pancreas Cancer
        • 5.2.1.3. Intestinal Cancer
      • 5.2.2. Global Sunitinib Malate by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacy
        • 5.2.2.2. Retail Drug Stores
      • 5.2.3. Global Sunitinib Malate by: Dosage (Value)
        • 5.2.3.1. 12.5mg
        • 5.2.3.2. 25mg
        • 5.2.3.3. 37.5mg
        • 5.2.3.4. 50mg
      • 5.2.4. Global Sunitinib Malate by: Side Effects (Value)
        • 5.2.4.1. Allergic Reaction
        • 5.2.4.2. Severe Dizziness
        • 5.2.4.3. Trouble Breathing
        • 5.2.4.4. Swelling (Face/Tongue/Throat)
        • 5.2.4.5. Others
      • 5.2.5. Global Sunitinib Malate Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Sunitinib Malate (Volume)
      • 5.3.1. Global Sunitinib Malate by: Application (Volume)
        • 5.3.1.1. Kidney Cancer
        • 5.3.1.2. Pancreas Cancer
        • 5.3.1.3. Intestinal Cancer
      • 5.3.2. Global Sunitinib Malate by: Distribution Channel (Volume)
        • 5.3.2.1. Hospital Pharmacy
        • 5.3.2.2. Retail Drug Stores
      • 5.3.3. Global Sunitinib Malate by: Dosage (Volume)
        • 5.3.3.1. 12.5mg
        • 5.3.3.2. 25mg
        • 5.3.3.3. 37.5mg
        • 5.3.3.4. 50mg
      • 5.3.4. Global Sunitinib Malate by: Side Effects (Volume)
        • 5.3.4.1. Allergic Reaction
        • 5.3.4.2. Severe Dizziness
        • 5.3.4.3. Trouble Breathing
        • 5.3.4.4. Swelling (Face/Tongue/Throat)
        • 5.3.4.5. Others
      • 5.3.5. Global Sunitinib Malate Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Sunitinib Malate (Price)
  • 6. Sunitinib Malate: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. PV Pharma (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Taj Pharma Group (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
  • 7. Global Sunitinib Malate Sale, by Application, Distribution Channel, Dosage, Side Effects and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Sunitinib Malate (Value)
      • 7.2.1. Global Sunitinib Malate by: Application (Value)
        • 7.2.1.1. Kidney Cancer
        • 7.2.1.2. Pancreas Cancer
        • 7.2.1.3. Intestinal Cancer
      • 7.2.2. Global Sunitinib Malate by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacy
        • 7.2.2.2. Retail Drug Stores
      • 7.2.3. Global Sunitinib Malate by: Dosage (Value)
        • 7.2.3.1. 12.5mg
        • 7.2.3.2. 25mg
        • 7.2.3.3. 37.5mg
        • 7.2.3.4. 50mg
      • 7.2.4. Global Sunitinib Malate by: Side Effects (Value)
        • 7.2.4.1. Allergic Reaction
        • 7.2.4.2. Severe Dizziness
        • 7.2.4.3. Trouble Breathing
        • 7.2.4.4. Swelling (Face/Tongue/Throat)
        • 7.2.4.5. Others
      • 7.2.5. Global Sunitinib Malate Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Sunitinib Malate (Volume)
      • 7.3.1. Global Sunitinib Malate by: Application (Volume)
        • 7.3.1.1. Kidney Cancer
        • 7.3.1.2. Pancreas Cancer
        • 7.3.1.3. Intestinal Cancer
      • 7.3.2. Global Sunitinib Malate by: Distribution Channel (Volume)
        • 7.3.2.1. Hospital Pharmacy
        • 7.3.2.2. Retail Drug Stores
      • 7.3.3. Global Sunitinib Malate by: Dosage (Volume)
        • 7.3.3.1. 12.5mg
        • 7.3.3.2. 25mg
        • 7.3.3.3. 37.5mg
        • 7.3.3.4. 50mg
      • 7.3.4. Global Sunitinib Malate by: Side Effects (Volume)
        • 7.3.4.1. Allergic Reaction
        • 7.3.4.2. Severe Dizziness
        • 7.3.4.3. Trouble Breathing
        • 7.3.4.4. Swelling (Face/Tongue/Throat)
        • 7.3.4.5. Others
      • 7.3.5. Global Sunitinib Malate Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Sunitinib Malate (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Sunitinib Malate: by Application(USD Million)
  • Table 2. Sunitinib Malate Kidney Cancer , by Region USD Million (2015-2020)
  • Table 3. Sunitinib Malate Pancreas Cancer , by Region USD Million (2015-2020)
  • Table 4. Sunitinib Malate Intestinal Cancer , by Region USD Million (2015-2020)
  • Table 5. Sunitinib Malate: by Distribution Channel(USD Million)
  • Table 6. Sunitinib Malate Hospital Pharmacy , by Region USD Million (2015-2020)
  • Table 7. Sunitinib Malate Retail Drug Stores , by Region USD Million (2015-2020)
  • Table 8. Sunitinib Malate: by Dosage(USD Million)
  • Table 9. Sunitinib Malate 12.5mg , by Region USD Million (2015-2020)
  • Table 10. Sunitinib Malate 25mg , by Region USD Million (2015-2020)
  • Table 11. Sunitinib Malate 37.5mg , by Region USD Million (2015-2020)
  • Table 12. Sunitinib Malate 50mg , by Region USD Million (2015-2020)
  • Table 13. Sunitinib Malate: by Side Effects(USD Million)
  • Table 14. Sunitinib Malate Allergic Reaction , by Region USD Million (2015-2020)
  • Table 15. Sunitinib Malate Severe Dizziness , by Region USD Million (2015-2020)
  • Table 16. Sunitinib Malate Trouble Breathing , by Region USD Million (2015-2020)
  • Table 17. Sunitinib Malate Swelling (Face/Tongue/Throat) , by Region USD Million (2015-2020)
  • Table 18. Sunitinib Malate Others , by Region USD Million (2015-2020)
  • Table 19. South America Sunitinib Malate, by Country USD Million (2015-2020)
  • Table 20. South America Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 21. South America Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 22. South America Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 23. South America Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 24. Brazil Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 25. Brazil Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 26. Brazil Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 27. Brazil Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 28. Argentina Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 29. Argentina Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 30. Argentina Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 31. Argentina Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 32. Rest of South America Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 33. Rest of South America Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 34. Rest of South America Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 35. Rest of South America Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 36. Asia Pacific Sunitinib Malate, by Country USD Million (2015-2020)
  • Table 37. Asia Pacific Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 38. Asia Pacific Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 39. Asia Pacific Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 40. Asia Pacific Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 41. China Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 42. China Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 43. China Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 44. China Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 45. Japan Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 46. Japan Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 47. Japan Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 48. Japan Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 49. India Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 50. India Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 51. India Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 52. India Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 53. South Korea Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 54. South Korea Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 55. South Korea Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 56. South Korea Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 57. Taiwan Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 58. Taiwan Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 59. Taiwan Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 60. Taiwan Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 61. Australia Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 62. Australia Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 63. Australia Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 64. Australia Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 69. Europe Sunitinib Malate, by Country USD Million (2015-2020)
  • Table 70. Europe Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 71. Europe Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 72. Europe Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 73. Europe Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 74. Germany Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 75. Germany Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 76. Germany Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 77. Germany Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 78. France Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 79. France Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 80. France Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 81. France Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 82. Italy Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 83. Italy Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 84. Italy Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 85. Italy Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 86. United Kingdom Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 87. United Kingdom Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 88. United Kingdom Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 89. United Kingdom Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 90. Netherlands Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 91. Netherlands Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 92. Netherlands Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 93. Netherlands Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 94. Rest of Europe Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 95. Rest of Europe Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 96. Rest of Europe Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 97. Rest of Europe Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 98. MEA Sunitinib Malate, by Country USD Million (2015-2020)
  • Table 99. MEA Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 100. MEA Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 101. MEA Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 102. MEA Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 103. Middle East Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 104. Middle East Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 105. Middle East Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 106. Middle East Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 107. Africa Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 108. Africa Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 109. Africa Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 110. Africa Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 111. North America Sunitinib Malate, by Country USD Million (2015-2020)
  • Table 112. North America Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 113. North America Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 114. North America Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 115. North America Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 116. United States Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 117. United States Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 118. United States Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 119. United States Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 120. Canada Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 121. Canada Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 122. Canada Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 123. Canada Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 124. Mexico Sunitinib Malate, by Application USD Million (2015-2020)
  • Table 125. Mexico Sunitinib Malate, by Distribution Channel USD Million (2015-2020)
  • Table 126. Mexico Sunitinib Malate, by Dosage USD Million (2015-2020)
  • Table 127. Mexico Sunitinib Malate, by Side Effects USD Million (2015-2020)
  • Table 128. Sunitinib Malate Sales: by Application(K Tons)
  • Table 129. Sunitinib Malate Sales Kidney Cancer , by Region K Tons (2015-2020)
  • Table 130. Sunitinib Malate Sales Pancreas Cancer , by Region K Tons (2015-2020)
  • Table 131. Sunitinib Malate Sales Intestinal Cancer , by Region K Tons (2015-2020)
  • Table 132. Sunitinib Malate Sales: by Distribution Channel(K Tons)
  • Table 133. Sunitinib Malate Sales Hospital Pharmacy , by Region K Tons (2015-2020)
  • Table 134. Sunitinib Malate Sales Retail Drug Stores , by Region K Tons (2015-2020)
  • Table 135. Sunitinib Malate Sales: by Dosage(K Tons)
  • Table 136. Sunitinib Malate Sales 12.5mg , by Region K Tons (2015-2020)
  • Table 137. Sunitinib Malate Sales 25mg , by Region K Tons (2015-2020)
  • Table 138. Sunitinib Malate Sales 37.5mg , by Region K Tons (2015-2020)
  • Table 139. Sunitinib Malate Sales 50mg , by Region K Tons (2015-2020)
  • Table 140. Sunitinib Malate Sales: by Side Effects(K Tons)
  • Table 141. Sunitinib Malate Sales Allergic Reaction , by Region K Tons (2015-2020)
  • Table 142. Sunitinib Malate Sales Severe Dizziness , by Region K Tons (2015-2020)
  • Table 143. Sunitinib Malate Sales Trouble Breathing , by Region K Tons (2015-2020)
  • Table 144. Sunitinib Malate Sales Swelling (Face/Tongue/Throat) , by Region K Tons (2015-2020)
  • Table 145. Sunitinib Malate Sales Others , by Region K Tons (2015-2020)
  • Table 146. South America Sunitinib Malate Sales, by Country K Tons (2015-2020)
  • Table 147. South America Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 148. South America Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 149. South America Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 150. South America Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 151. Brazil Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 152. Brazil Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 153. Brazil Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 154. Brazil Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 155. Argentina Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 156. Argentina Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 157. Argentina Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 158. Argentina Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 159. Rest of South America Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 160. Rest of South America Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 161. Rest of South America Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 162. Rest of South America Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 163. Asia Pacific Sunitinib Malate Sales, by Country K Tons (2015-2020)
  • Table 164. Asia Pacific Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 165. Asia Pacific Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 166. Asia Pacific Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 167. Asia Pacific Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 168. China Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 169. China Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 170. China Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 171. China Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 172. Japan Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 173. Japan Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 174. Japan Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 175. Japan Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 176. India Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 177. India Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 178. India Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 179. India Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 180. South Korea Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 181. South Korea Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 182. South Korea Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 183. South Korea Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 184. Taiwan Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 185. Taiwan Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 186. Taiwan Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 187. Taiwan Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 188. Australia Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 189. Australia Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 190. Australia Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 191. Australia Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 192. Rest of Asia-Pacific Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 193. Rest of Asia-Pacific Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 194. Rest of Asia-Pacific Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 195. Rest of Asia-Pacific Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 196. Europe Sunitinib Malate Sales, by Country K Tons (2015-2020)
  • Table 197. Europe Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 198. Europe Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 199. Europe Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 200. Europe Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 201. Germany Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 202. Germany Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 203. Germany Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 204. Germany Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 205. France Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 206. France Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 207. France Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 208. France Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 209. Italy Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 210. Italy Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 211. Italy Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 212. Italy Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 213. United Kingdom Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 214. United Kingdom Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 215. United Kingdom Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 216. United Kingdom Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 217. Netherlands Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 218. Netherlands Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 219. Netherlands Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 220. Netherlands Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 221. Rest of Europe Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 222. Rest of Europe Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 223. Rest of Europe Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 224. Rest of Europe Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 225. MEA Sunitinib Malate Sales, by Country K Tons (2015-2020)
  • Table 226. MEA Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 227. MEA Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 228. MEA Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 229. MEA Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 230. Middle East Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 231. Middle East Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 232. Middle East Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 233. Middle East Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 234. Africa Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 235. Africa Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 236. Africa Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 237. Africa Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 238. North America Sunitinib Malate Sales, by Country K Tons (2015-2020)
  • Table 239. North America Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 240. North America Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 241. North America Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 242. North America Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 243. United States Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 244. United States Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 245. United States Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 246. United States Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 247. Canada Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 248. Canada Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 249. Canada Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 250. Canada Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 251. Mexico Sunitinib Malate Sales, by Application K Tons (2015-2020)
  • Table 252. Mexico Sunitinib Malate Sales, by Distribution Channel K Tons (2015-2020)
  • Table 253. Mexico Sunitinib Malate Sales, by Dosage K Tons (2015-2020)
  • Table 254. Mexico Sunitinib Malate Sales, by Side Effects K Tons (2015-2020)
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Sunitinib Malate: by Application(USD Million)
  • Table 259. Sunitinib Malate Kidney Cancer , by Region USD Million (2021-2026)
  • Table 260. Sunitinib Malate Pancreas Cancer , by Region USD Million (2021-2026)
  • Table 261. Sunitinib Malate Intestinal Cancer , by Region USD Million (2021-2026)
  • Table 262. Sunitinib Malate: by Distribution Channel(USD Million)
  • Table 263. Sunitinib Malate Hospital Pharmacy , by Region USD Million (2021-2026)
  • Table 264. Sunitinib Malate Retail Drug Stores , by Region USD Million (2021-2026)
  • Table 265. Sunitinib Malate: by Dosage(USD Million)
  • Table 266. Sunitinib Malate 12.5mg , by Region USD Million (2021-2026)
  • Table 267. Sunitinib Malate 25mg , by Region USD Million (2021-2026)
  • Table 268. Sunitinib Malate 37.5mg , by Region USD Million (2021-2026)
  • Table 269. Sunitinib Malate 50mg , by Region USD Million (2021-2026)
  • Table 270. Sunitinib Malate: by Side Effects(USD Million)
  • Table 271. Sunitinib Malate Allergic Reaction , by Region USD Million (2021-2026)
  • Table 272. Sunitinib Malate Severe Dizziness , by Region USD Million (2021-2026)
  • Table 273. Sunitinib Malate Trouble Breathing , by Region USD Million (2021-2026)
  • Table 274. Sunitinib Malate Swelling (Face/Tongue/Throat) , by Region USD Million (2021-2026)
  • Table 275. Sunitinib Malate Others , by Region USD Million (2021-2026)
  • Table 276. South America Sunitinib Malate, by Country USD Million (2021-2026)
  • Table 277. South America Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 278. South America Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 279. South America Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 280. South America Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 281. Brazil Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 282. Brazil Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 283. Brazil Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 284. Brazil Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 285. Argentina Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 286. Argentina Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 287. Argentina Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 288. Argentina Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 289. Rest of South America Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 290. Rest of South America Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 291. Rest of South America Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 292. Rest of South America Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 293. Asia Pacific Sunitinib Malate, by Country USD Million (2021-2026)
  • Table 294. Asia Pacific Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 295. Asia Pacific Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 296. Asia Pacific Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 297. Asia Pacific Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 298. China Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 299. China Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 300. China Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 301. China Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 302. Japan Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 303. Japan Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 304. Japan Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 305. Japan Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 306. India Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 307. India Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 308. India Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 309. India Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 310. South Korea Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 311. South Korea Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 312. South Korea Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 313. South Korea Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 314. Taiwan Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 315. Taiwan Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 316. Taiwan Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 317. Taiwan Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 318. Australia Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 319. Australia Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 320. Australia Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 321. Australia Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 322. Rest of Asia-Pacific Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 323. Rest of Asia-Pacific Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 324. Rest of Asia-Pacific Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 325. Rest of Asia-Pacific Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 326. Europe Sunitinib Malate, by Country USD Million (2021-2026)
  • Table 327. Europe Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 328. Europe Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 329. Europe Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 330. Europe Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 331. Germany Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 332. Germany Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 333. Germany Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 334. Germany Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 335. France Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 336. France Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 337. France Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 338. France Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 339. Italy Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 340. Italy Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 341. Italy Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 342. Italy Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 343. United Kingdom Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 344. United Kingdom Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 345. United Kingdom Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 346. United Kingdom Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 347. Netherlands Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 348. Netherlands Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 349. Netherlands Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 350. Netherlands Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 351. Rest of Europe Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 352. Rest of Europe Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 353. Rest of Europe Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 354. Rest of Europe Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 355. MEA Sunitinib Malate, by Country USD Million (2021-2026)
  • Table 356. MEA Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 357. MEA Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 358. MEA Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 359. MEA Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 360. Middle East Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 361. Middle East Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 362. Middle East Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 363. Middle East Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 364. Africa Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 365. Africa Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 366. Africa Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 367. Africa Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 368. North America Sunitinib Malate, by Country USD Million (2021-2026)
  • Table 369. North America Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 370. North America Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 371. North America Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 372. North America Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 373. United States Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 374. United States Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 375. United States Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 376. United States Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 377. Canada Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 378. Canada Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 379. Canada Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 380. Canada Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 381. Mexico Sunitinib Malate, by Application USD Million (2021-2026)
  • Table 382. Mexico Sunitinib Malate, by Distribution Channel USD Million (2021-2026)
  • Table 383. Mexico Sunitinib Malate, by Dosage USD Million (2021-2026)
  • Table 384. Mexico Sunitinib Malate, by Side Effects USD Million (2021-2026)
  • Table 385. Sunitinib Malate Sales: by Application(K Tons)
  • Table 386. Sunitinib Malate Sales Kidney Cancer , by Region K Tons (2021-2026)
  • Table 387. Sunitinib Malate Sales Pancreas Cancer , by Region K Tons (2021-2026)
  • Table 388. Sunitinib Malate Sales Intestinal Cancer , by Region K Tons (2021-2026)
  • Table 389. Sunitinib Malate Sales: by Distribution Channel(K Tons)
  • Table 390. Sunitinib Malate Sales Hospital Pharmacy , by Region K Tons (2021-2026)
  • Table 391. Sunitinib Malate Sales Retail Drug Stores , by Region K Tons (2021-2026)
  • Table 392. Sunitinib Malate Sales: by Dosage(K Tons)
  • Table 393. Sunitinib Malate Sales 12.5mg , by Region K Tons (2021-2026)
  • Table 394. Sunitinib Malate Sales 25mg , by Region K Tons (2021-2026)
  • Table 395. Sunitinib Malate Sales 37.5mg , by Region K Tons (2021-2026)
  • Table 396. Sunitinib Malate Sales 50mg , by Region K Tons (2021-2026)
  • Table 397. Sunitinib Malate Sales: by Side Effects(K Tons)
  • Table 398. Sunitinib Malate Sales Allergic Reaction , by Region K Tons (2021-2026)
  • Table 399. Sunitinib Malate Sales Severe Dizziness , by Region K Tons (2021-2026)
  • Table 400. Sunitinib Malate Sales Trouble Breathing , by Region K Tons (2021-2026)
  • Table 401. Sunitinib Malate Sales Swelling (Face/Tongue/Throat) , by Region K Tons (2021-2026)
  • Table 402. Sunitinib Malate Sales Others , by Region K Tons (2021-2026)
  • Table 403. South America Sunitinib Malate Sales, by Country K Tons (2021-2026)
  • Table 404. South America Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 405. South America Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 406. South America Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 407. South America Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 408. Brazil Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 409. Brazil Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 410. Brazil Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 411. Brazil Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 412. Argentina Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 413. Argentina Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 414. Argentina Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 415. Argentina Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 416. Rest of South America Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 417. Rest of South America Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 418. Rest of South America Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 419. Rest of South America Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 420. Asia Pacific Sunitinib Malate Sales, by Country K Tons (2021-2026)
  • Table 421. Asia Pacific Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 422. Asia Pacific Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 423. Asia Pacific Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 424. Asia Pacific Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 425. China Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 426. China Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 427. China Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 428. China Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 429. Japan Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 430. Japan Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 431. Japan Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 432. Japan Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 433. India Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 434. India Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 435. India Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 436. India Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 437. South Korea Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 438. South Korea Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 439. South Korea Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 440. South Korea Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 441. Taiwan Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 442. Taiwan Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 443. Taiwan Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 444. Taiwan Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 445. Australia Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 446. Australia Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 447. Australia Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 448. Australia Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 449. Rest of Asia-Pacific Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 450. Rest of Asia-Pacific Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 451. Rest of Asia-Pacific Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 452. Rest of Asia-Pacific Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 453. Europe Sunitinib Malate Sales, by Country K Tons (2021-2026)
  • Table 454. Europe Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 455. Europe Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 456. Europe Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 457. Europe Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 458. Germany Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 459. Germany Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 460. Germany Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 461. Germany Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 462. France Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 463. France Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 464. France Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 465. France Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 466. Italy Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 467. Italy Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 468. Italy Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 469. Italy Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 470. United Kingdom Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 471. United Kingdom Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 472. United Kingdom Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 473. United Kingdom Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 474. Netherlands Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 475. Netherlands Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 476. Netherlands Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 477. Netherlands Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 478. Rest of Europe Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 479. Rest of Europe Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 480. Rest of Europe Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 481. Rest of Europe Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 482. MEA Sunitinib Malate Sales, by Country K Tons (2021-2026)
  • Table 483. MEA Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 484. MEA Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 485. MEA Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 486. MEA Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 487. Middle East Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 488. Middle East Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 489. Middle East Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 490. Middle East Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 491. Africa Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 492. Africa Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 493. Africa Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 494. Africa Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 495. North America Sunitinib Malate Sales, by Country K Tons (2021-2026)
  • Table 496. North America Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 497. North America Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 498. North America Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 499. North America Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 500. United States Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 501. United States Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 502. United States Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 503. United States Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 504. Canada Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 505. Canada Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 506. Canada Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 507. Canada Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 508. Mexico Sunitinib Malate Sales, by Application K Tons (2021-2026)
  • Table 509. Mexico Sunitinib Malate Sales, by Distribution Channel K Tons (2021-2026)
  • Table 510. Mexico Sunitinib Malate Sales, by Dosage K Tons (2021-2026)
  • Table 511. Mexico Sunitinib Malate Sales, by Side Effects K Tons (2021-2026)
  • Table 512. Research Programs/Design for This Report
  • Table 513. Key Data Information from Secondary Sources
  • Table 514. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Sunitinib Malate: by Application USD Million (2015-2020)
  • Figure 5. Global Sunitinib Malate: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Sunitinib Malate: by Dosage USD Million (2015-2020)
  • Figure 7. Global Sunitinib Malate: by Side Effects USD Million (2015-2020)
  • Figure 8. South America Sunitinib Malate Share (%), by Country
  • Figure 9. Asia Pacific Sunitinib Malate Share (%), by Country
  • Figure 10. Europe Sunitinib Malate Share (%), by Country
  • Figure 11. MEA Sunitinib Malate Share (%), by Country
  • Figure 12. North America Sunitinib Malate Share (%), by Country
  • Figure 13. Global Sunitinib Malate: by Application K Tons (2015-2020)
  • Figure 14. Global Sunitinib Malate: by Distribution Channel K Tons (2015-2020)
  • Figure 15. Global Sunitinib Malate: by Dosage K Tons (2015-2020)
  • Figure 16. Global Sunitinib Malate: by Side Effects K Tons (2015-2020)
  • Figure 17. South America Sunitinib Malate Share (%), by Country
  • Figure 18. Asia Pacific Sunitinib Malate Share (%), by Country
  • Figure 19. Europe Sunitinib Malate Share (%), by Country
  • Figure 20. MEA Sunitinib Malate Share (%), by Country
  • Figure 21. North America Sunitinib Malate Share (%), by Country
  • Figure 22. Global Sunitinib Malate share by Players 2020 (%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer (United States) Revenue: by Geography 2020
  • Figure 26. PV Pharma (India) Revenue, Net Income and Gross profit
  • Figure 27. PV Pharma (India) Revenue: by Geography 2020
  • Figure 28. Taj Pharma Group (India) Revenue, Net Income and Gross profit
  • Figure 29. Taj Pharma Group (India) Revenue: by Geography 2020
  • Figure 30. Global Sunitinib Malate: by Application USD Million (2021-2026)
  • Figure 31. Global Sunitinib Malate: by Distribution Channel USD Million (2021-2026)
  • Figure 32. Global Sunitinib Malate: by Dosage USD Million (2021-2026)
  • Figure 33. Global Sunitinib Malate: by Side Effects USD Million (2021-2026)
  • Figure 34. South America Sunitinib Malate Share (%), by Country
  • Figure 35. Asia Pacific Sunitinib Malate Share (%), by Country
  • Figure 36. Europe Sunitinib Malate Share (%), by Country
  • Figure 37. MEA Sunitinib Malate Share (%), by Country
  • Figure 38. North America Sunitinib Malate Share (%), by Country
  • Figure 39. Global Sunitinib Malate: by Application K Tons (2021-2026)
  • Figure 40. Global Sunitinib Malate: by Distribution Channel K Tons (2021-2026)
  • Figure 41. Global Sunitinib Malate: by Dosage K Tons (2021-2026)
  • Figure 42. Global Sunitinib Malate: by Side Effects K Tons (2021-2026)
  • Figure 43. South America Sunitinib Malate Share (%), by Country
  • Figure 44. Asia Pacific Sunitinib Malate Share (%), by Country
  • Figure 45. Europe Sunitinib Malate Share (%), by Country
  • Figure 46. MEA Sunitinib Malate Share (%), by Country
  • Figure 47. North America Sunitinib Malate Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Pfizer (United States)
  • PV Pharma (India)
  • Taj Pharma Group (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation